Results 211 to 220 of about 28,675 (247)
Some of the next articles are maybe not open access.
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
Drugs, 2020Alemtuzumab (Lemtrada®) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse rates (in treatment-naïve or ...
openaire +2 more sources
TRAF2 is Upregulated in Relapsing-Remitting Multiple Sclerosis
Neuroimmunomodulation, 2013<b><i>Objective:</i></b> To elucidate the role of tumor necrosis factor (TNF) receptor signal transduction in multiple sclerosis (MS). <b><i>Methods:</i></b> We performed a cross-sectional analysis of the gene expression of TRAF2 (TNF receptor-associated factor 2) and RIP (receptor-interacting protein) in
Reinhard, Reuß +5 more
openaire +2 more sources
Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis
Expert Review of Neurotherapeutics, 2010Multiple sclerosis (MS) is an autoimmune disorder characterized by CNS inflammation, demyelination and cellular damage with atrophy. Most patients with MS initially present with a relapsing-remitting course, with periodic episodes of neurologic symptomatology that do not follow a predictable pattern. In order to maintain a stable clinical course, it is
openaire +2 more sources
Daclizumab for the treatment of relapsing-remitting multiple sclerosis
Expert Opinion on Biological Therapy, 2017Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system. Over the last two decades, the number of therapeutic options for the treatment of relapsing remitting MS (RRMS) has been constantly growing, providing new treatment options to patients.
Marina, Herwerth, Bernhard, Hemmer
openaire +2 more sources
Mycophenolate mofetil for relapsing-remitting multiple sclerosis
Cochrane Database of Systematic Reviews, 2012Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system and a leading cause of disability in young and middle-aged adults. Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been used for the prevention of allograft rejection after renal, cardiac, or liver transplant and in patients with autoimmune diseases ...
Yousheng, Xiao +3 more
openaire +2 more sources
Considerations in the treatment of relapsing-remitting multiple sclerosis
Neurology, 2002Disease-modifying drugs are available in the United States for the treatment of relapsing-remitting multiple sclerosis (RRMS), including interferon (IFN) beta-1a, IFNbeta-1b, and glatiramer acetate. Another formulation of IFNbeta-1a is available in Europe, Canada, and other countries.
openaire +2 more sources
Ozanimod for the treatment of relapsing remitting multiple sclerosis
Expert Opinion on Pharmacotherapy, 2018Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing remitting multiple sclerosis. Extensive clinical experience has become available for the related compound fingolimod, favoring the sphingosine 1-phosphate therapeutic concept. Off-target effects have been attributed to
Ludwig, Rasche, Friedemann, Paul
openaire +2 more sources
Laquinimod in the treatment of relapsing remitting multiple sclerosis
Expert Opinion on Drug Metabolism & Toxicology, 2016Laquinimod is a new once-daily oral administrable agent, which is under investigation in a phase 3 clinical trial for relapsing remitting multiple sclerosis (RRMS) and in a phase 2 clinical trial for primary progressive MS (PPMS).The pharmacokinetic, pharmacodynamic and the safety profiles of laquinimod are covered in this review.
Undine Hainke +2 more
openaire +2 more sources
FADD Is Upregulated in Relapsing Remitting Multiple Sclerosis
Neuroimmunomodulation, 2014<b><i>Objective:</i></b> To elucidate the role of tumor necrosis factor (TNF) receptor signal transduction in multiple sclerosis (MS). <b><i>Methods:</i></b> We performed a cross-sectional analysis of the gene expression of TNF receptor-associated death domain protein (TRADD) and Fas-associated death ...
Reinhard, Reuss +5 more
openaire +2 more sources
Teriflunomide for the treatment of relapsing–remitting multiple sclerosis
Expert Review of Clinical Immunology, 2014Teriflunomide, a once-daily, oral disease-modifying therapy, is a valuable new treatment option for the management of patients with relapsing-remitting multiple sclerosis. This article reviews key efficacy and safety data arising from pivotal teriflunomide studies that demonstrate the utility in treating both treatment-naïve patients and those ...
openaire +2 more sources